Skip to content

Serum β-synuclein predicts dementia conversion and mortality beyond amyloid-β and phospho-tau.

Oct 2026 · Brain : a journal of neurology · 0 citations
Medicine

TL;DR

Serum β-synuclein provided prognostic information largely independent of CSF Aβ42/Aβ40 across all endpoints and of pTau181 for survival outcomes, while sharing substantial prognostic variance beyond CSF biomarkers.

Abstract

Synaptic dysfunction is among the earliest pathological events in Alzheimer's disease and among the strongest neuropathological correlates of cognitive impairment, yet blood-based synaptic biomarkers are lacking. Whether serum β-synuclein provides prognostic information independent of established amyloid-β (A; CSF Aβ42/Aβ40 ratio) and tau (T1; CSF pTau181) biomarkers has not been determined. We studied 259 non-demented individuals with subjective or mild cognitive impairment from a single-centre memory clinic, classified by CSF biomarkers using externally validated cut-offs into A-T1- controls (n = 97), A-T1+ PASSED ('pTau and Aβ surge with subtle deterioration', n = 65), and A + T1+ Alzheimer's disease (n = 97), with parallel analyses using Aβ40-normalised pTau181. Endpoints comprised dementia conversion (n = 185, median follow-up 4.1 years), all-cause mortality (n = 258, median 7.0 years), longitudinal MMSE trajectories (n = 185), and regional brain volumes (n = 137). Independence from CSF biomarkers was quantified through systematic effect attenuation analysis. Serum β-synuclein was selectively elevated in the Alzheimer's disease group (Cohen's d = 0.69 vs controls, P < 0.001) but not in PASSED individuals (P = 0.40), and was more strongly associated with CSF pTau181 (r = 0.36) than with the Aβ42/Aβ40 ratio (r = -0.20) across the cohort. Each standard deviation increase was associated with higher risk of dementia conversion (hazard ratio (HR) = 1.40; 95% CI: 1.11, 1.77; P = 0.005), faster cognitive decline (-0.11 SD/year, 95% CI: -0.18, -0.04, P = 0.002, corresponding to -0.20 MMSE points/year), and higher mortality (HR = 1.33; 95% CI: 1.07, 1.65; P = 0.010). For dementia conversion and mortality, adjustment for continuous CSF pTau181 and Aβ42/Aβ40 produced minimal attenuation (≤13%). Both associations were preserved under Aβ40-normalised T1 staging but not against continuous pTau181 normalised to CSF Aβ40. For cognitive decline, β-synuclein's effect remained significant after Aβ42/Aβ40 adjustment (25% attenuation; P = 0.007) but was substantially attenuated by pTau181 (58.5%; P = 0.186). Serum β-synuclein was associated with lower bilateral temporal lobe volume-the only lobar regions to survive hierarchical testing-with sub-regional involvement spanning the hippocampi, entorhinal cortex and parahippocampal gyrus, and explained 5.0-8.9% of unique variance beyond CSF biomarkers. Plasma glial fibrillary acidic protein (GFAP) showed a strong association with β-synuclein, estimated in the PASSED subgroup (β=0.34 per SD, P < 0.001). Serum β-synuclein provided prognostic information largely independent of CSF Aβ42/Aβ40 across all endpoints and of pTau181 for survival outcomes, while sharing substantial prognostic variance with pTau181 for cognitive trajectory, supporting its candidacy as a blood-based synaptic complement to core Alzheimer's disease biomarkers.

View source

Similar papers

Open access Oct 2026

The Association of Amyloid‐β and Tau With Synaptic Dysfunction in Alzheimer's Disease

Tau pathology showed strong associations with synaptic biomarkers, with a potential mediating role in the association between amyloid pathology and synaptic dysfunction, and these findings support a central role of tau‐related processes in synaptic dysfunction in AD.

Fausto Roveta, Augusto J. Mendes, V. Garibotto et al. · 0 citations
Open access Oct 2026

α-Synuclein Seed Amplification Status Modifies the Relationship Between Plasma p-tau217, Amyloid and Fibrillar Tau

Abstract Background. Plasma p-tau217 is sufficient to establish a biological diagnosis of Alzheimer's disease (AD) and is and is increasingly used as a routine diagnostic tool. Many patients with AD also carry α-synuclein pathology, detectable by cerebrospinal fluid (CSF) seed amplification assay (αSynSAA). Seeding act...

Í. Rodríguez-Baz, Rosa Ferrer, M. Falip et al. · 0 citations
Open access Oct 2026

Amyloid, p‐tau, neurofilament light, and α‐synuclein cerebrospinal fluid biomarkers across Alzheimer's disease, dementia with Lewy bodies, and Parkinson's disease

Amyloid and tau positivity in DLB were associated with worse global cognitive outcomes, but not with motor performance, and NfL levels were elevated across diseases, and total α‐synuclein levels were associated with tau positivity.

Marianna Rizzo, C. Teunissen, H. Zetterberg et al. · 0 citations
Open access Oct 2026

Clinical and biomarker predictors of α-synuclein seeding in cognitive impairment and motor parkinsonism.

Dopamine transporter (DAT) imaging and α-synuclein seed amplification assay (SAA) are biomarkers for Lewy body disease (LBD). We aimed to identify clinical and biomarker factors associated with SAA positivity in patients with cognitive impairment and frequent motor parkinsonism. Dual-phase DAT positron emission tomogra...

Byoung Seok Ye, Lawren VandeVrede, Su-Hee Jeon et al. · 0 citations
Review Open access Sep 2026

Plasma Neurofilament Light Chain as a Complementary Biomarker for Alzheimer’s Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis

Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by cognitive decline and memory loss, ultimately leading to a loss of independence and reduced quality of life. As current treatments are most effective in the early stages, reliable blood-based biomarkers are required for early diagnosis, therapeut...

Ka Young Kim, Ki-Young Shin, Keun-A Chang · 0 citations
Nov 2026

Midlife and Late-Life Alzheimer Disease Blood Biomarkers and 11-Year Cognitive Decline.

BACKGROUND AND OBJECTIVES Plasma biomarkers of Alzheimer disease (AD) neuropathology (amyloid-β42 to amyloid β40 [Aβ42/40] ratio, phosphorylated tau at threonine [p-tau181]), neurodegeneration (neurofilament light [NfL]), and neuroinflammation (glial fibrillary acidic protein [GFAP]) in late-life are associated with co...

Jason R. Smith, J. Pike, Yi-Fei Lu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.